Biocon Biologics Achieves U.S. Market Entry for Yesafili Biosimilar, Settles Patent Litigation with Regeneron

Biocon Biologics has successfully established approval for U.S. market entry of its biosimilar Eylea (aflibercept) product, Yesafili, in a major development of its expansion strategy across the globe. Furthermore, the firm has entered a settlement agreement with Regeneron Pharmaceuticals, putting to rest pending patent litigation for Yesafili.

Key Highlights:
Regulatory Approval: Biocon Biologics has received the required approvals to launch Yesafili in the U.S., demonstrating its dedication to affordable and accessible biologics.

Market Strategy: The biosimilar competes for the treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME) market, battling Regeneron's Eylea.

Launch Timeline: Yesafili is likely to launch during the second half of 2026 or sooner, enhancing Biocon's position in the ophthalmology segment.

Patent Settlement: Biocon Biologics and Regeneron have settled all pending appeals, disposing of several patent infringement cases.

Growth Prospects: The launch will augment Biocon's revenue streams, growing its presence in the high-value ophthalmology market.

This settlement and entry into the market are a key milestone for Biocon Biologics, paving the way for a smoother launch of Yesafili while consolidating its leadership in biosimilars.

Source: Business Standard, Financial Express